Streetbeat News

Stock Prices

NUWE

Nuwellis shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 2:10 pm

LOCL

Local Bounti shares are trading higher despite the company reporting worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 2:09 pm

INTC

TSLA

TSM

Intel plans to cut 15% of its workforce as part of a $10 billion cost-reduction initiative aimed at regaining its technological leadership in the semiconductor industry. This move mirrors Tesla's earlier workforce reduction, which led to a significant stock rally. Investors are watching to see if Intel can replicate Tesla's success.

Portfolio Pulse from Surbhi Jain

August 13, 2024 | 2:06 pm

CSPI

CSPI shares are trading lower following the company's report of a year-over-year decrease in Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 2:03 pm

USFD

In the past three months, 6 analysts have provided ratings for US Foods Hldg (NYSE:USFD), ranging from bullish to indifferent. The average 12-month price target is $64.33, up 4.6% from the previous $61.50. Analysts from JP Morgan, Deutsche Bank, Piper Sandler, Wells Fargo, and Truist Securities have raised their price targets, reflecting positive sentiment. US Foods Hldg has shown strong financial performance with a 7.72% revenue growth rate, a net margin of 2.04%, and a debt-to-equity ratio of 0.98.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 2:01 pm

YMAB

Y-mAbs Therapeutics (NASDAQ:YMAB) has been analyzed by 5 analysts in the last three months, revealing a range of perspectives from bullish to bearish. Analysts have set a 12-month price target average of $20.4, with a high of $25.00 and a low of $11.00. Recent actions include rating adjustments and price target changes by analysts from firms like Morgan Stanley, HC Wainwright & Co., BMO Capital, Jones Trading, and Truist Securities. The company faces challenges with a -1.58% revenue decline over the past three months but shows strong financial metrics like net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 2:01 pm

TCRX

Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $12.6, with a high of $15.00 and a low of $10.00. The company's financial metrics indicate challenges in revenue growth, ROE, and ROA, but it maintains a strong net margin.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 2:00 pm

APO

Apollo Global Management (NYSE:APO) has significantly outperformed the market over the past 5 years, delivering an average annual return of 25.3%. A $100 investment in APO 5 years ago would now be worth $324.94. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 2:00 pm

MELI

MercadoLibre (NASDAQ:MELI) has significantly outperformed the market over the past 5 years, delivering an average annual return of 25.93%. A $1000 investment in MELI 5 years ago would be worth $3,059.14 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 2:00 pm

CMS

Over the past three months, six analysts have evaluated CMS Energy (NYSE:CMS), with opinions ranging from bullish to bearish. The average 12-month price target is $64.83, reflecting a 3.45% increase from the previous target. Analysts from Barclays, Guggenheim, Wells Fargo, Morgan Stanley, and Keybanc have adjusted their ratings and price targets, indicating varied expectations for CMS Energy's performance. The company has shown positive revenue growth and strong profitability but faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 2:00 pm